SharesGrow 7-Criteria Score
All 7 criteria scored · valuation-related highlighted on this page
Cell Source, Inc. (CLCS) .
本頁證實的標準:
- VALUE (0/100, 未通過) — 綜合估值評分低於60/100的通過門檻。
SharesGrow 綜合評分： 17/100 其中 0/7 項標準通過。
SharesGrow 7-Criteria Score
✗
健康
0/100
Debt-to-Equity & liquidity
→ Health
估值概覽 — CLCS
估值倍數
P/E (TTM)0.0
前瞻 P/EN/A
PEG 比率N/A
前瞻 PEGN/A
P/B 比率0.00
P/S 比率0.00
EV/EBITDA0.0
每股數據
EPS (TTM)$-0.15
每股帳面價值$0.00
每股營收$0.00
每股自由現金流$0.00
收益率與內在價值
盈利收益率N/A
股息收益率0.00%
P/E Ratio & Earnings Yield
每股盈餘 (EPS) 歷史
| Year |
EPS（稀釋） |
營收 |
淨利潤 |
淨利潤率 |
| 2015 |
$-0.10 |
$0.00 |
$-2.5M |
- |
| 2016 |
$-0.04 |
$0.00 |
$-968K |
- |
| 2017 |
$-0.12 |
$0.00 |
$-3.08M |
- |
| 2018 |
$-0.08 |
$0.00 |
$-2.12M |
- |
| 2019 |
$-0.18 |
$0.00 |
$-4.48M |
- |
| 2020 |
$-0.19 |
$0.00 |
$-4.56M |
- |
| 2021 |
$-0.19 |
$0.00 |
$-5.47M |
- |
| 2022 |
$-0.15 |
$0.00 |
$-5.17M |
- |
| 2023 |
$-0.17 |
$0.00 |
$-5.32M |
- |
| 2024 |
$-0.15 |
$0.00 |
$-4.77M |
- |
